Upstream mechanisms of glycogen synthase activation by insulin and insulin-like growth factor-I. Glycogen synthase activation is antagonized by wortmannin or LY294002 but not by rapamycin or by inhibiting p21ras.
This study was undertaken to define intracellular signaling pathways upstream to glycogen synthase activation. First, we examined the role of the two pathways of insulin signaling, Ras-dependent and wortmannin/LY294002-sensitive, in glycogen synthase activation. Although negative dominant Ras (Ras17N) induction in PC12 cells markedly decreased activities of mitogen-activated protein kinase (MAP) and pp90 S6 kinase in response to insulin or insulin-like growth factor I (IGF-I), activation of glycogen synthase by these agents was unaffected by negative dominant Ras induction. In contrast, wortmannin and 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002), inhibitors of phosphatidylinositol 3-kinase, antagonized glycogen synthase activation in response to insulin or IGF-I. Next, we examined the contribution of pp70 S6 kinase, one of the wortmannin/LY294002-sensitive signaling molecules on glycogen synthase activation. Immunosuppressant rapamycin completely blocked activation of pp70 S6 kinase by insulin or IGF-I, but rapamycin alone or in combination with induction of negative dominant Ras failed to antagonize glycogen synthase activation by these hormones. These data suggest that 1) activation of Ras-MAP kinase is not necessary for stimulation of glycogen synthase and 2) activation of wortmannin/LY294002-sensitive pathway, independent of pp70 S6 kinase, plays a key role in glycogen synthase regulation in PC12 cells.
Third Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Japan.
R
R
Yamamoto-Honda
K
K
Tobe
Y
Y
Kaburagi
K
K
Ueki
S
S
Asai
M
M
Yachi
M
M
Shirouzu
J
J
Yodoi
Y
Y
Akanuma
S
S
Yokoyama
D000595:Amino Acid Sequence; D000730:Androstadienes / Q000494:pharmacology; D000818:Animals; D002867:Chromones / Q000494:pharmacology; D004789:Enzyme Activation; D006006:Glycogen Synthase / Q000037:antagonists & inhibitors / Q000378:metabolism*; D007328:Insulin / Q000494:pharmacology*; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology*; D008969:Molecular Sequence Data; D009025:Morpholines / Q000494:pharmacology; D015689:Oncogene Protein p21(ras) / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000378:metabolism; D016716:PC12 Cells; D011090:Polyenes / Q000494:pharmacology; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D051381:Rats; D019893:Ribosomal Protein S6 Kinases; D020123:Sirolimus; D000077191:Wortmannin
D000730:Androstadienes; D002867:Chromones; D007328:Insulin; D009025:Morpholines; D011090:Polyenes; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; D007334:Insulin-Like Growth Factor I; D006006:Glycogen Synthase; D017346:Protein Serine-Threonine Kinases; D019893:Ribosomal Protein S6 Kinases; D015689:Oncogene Protein p21(ras); D020123:Sirolimus; D000077191:Wortmannin